Untargeted metabolomics for profiling oncogene-specific metabolic signatures of prostate cancer
Oncogene-associated metabolic signatures in prostate cancer, identified by an integrative analysis of cultured cells and murine and human tumors, suggest that AKT activation results in a glycolytic phenotype whereas MYC induces aberrant lipid metabolism. Heterogeneity in human tumors makes this simp...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905328/ https://www.ncbi.nlm.nih.gov/pubmed/27308491 http://dx.doi.org/10.1080/23723556.2014.1001197 |
_version_ | 1782437248622395392 |
---|---|
author | Priolo, Carmen Loda, Massimo |
author_facet | Priolo, Carmen Loda, Massimo |
author_sort | Priolo, Carmen |
collection | PubMed |
description | Oncogene-associated metabolic signatures in prostate cancer, identified by an integrative analysis of cultured cells and murine and human tumors, suggest that AKT activation results in a glycolytic phenotype whereas MYC induces aberrant lipid metabolism. Heterogeneity in human tumors makes this simplistic interpretation obtained from experimental models more challenging. Metabolic reprogramming as a function of distinct molecular aberrations has major diagnostic and therapeutic implications. |
format | Online Article Text |
id | pubmed-4905328 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-49053282016-06-15 Untargeted metabolomics for profiling oncogene-specific metabolic signatures of prostate cancer Priolo, Carmen Loda, Massimo Mol Cell Oncol Author's View Oncogene-associated metabolic signatures in prostate cancer, identified by an integrative analysis of cultured cells and murine and human tumors, suggest that AKT activation results in a glycolytic phenotype whereas MYC induces aberrant lipid metabolism. Heterogeneity in human tumors makes this simplistic interpretation obtained from experimental models more challenging. Metabolic reprogramming as a function of distinct molecular aberrations has major diagnostic and therapeutic implications. Taylor & Francis 2015-01-23 /pmc/articles/PMC4905328/ /pubmed/27308491 http://dx.doi.org/10.1080/23723556.2014.1001197 Text en © 2015 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted. |
spellingShingle | Author's View Priolo, Carmen Loda, Massimo Untargeted metabolomics for profiling oncogene-specific metabolic signatures of prostate cancer |
title | Untargeted metabolomics for profiling oncogene-specific metabolic signatures of prostate cancer |
title_full | Untargeted metabolomics for profiling oncogene-specific metabolic signatures of prostate cancer |
title_fullStr | Untargeted metabolomics for profiling oncogene-specific metabolic signatures of prostate cancer |
title_full_unstemmed | Untargeted metabolomics for profiling oncogene-specific metabolic signatures of prostate cancer |
title_short | Untargeted metabolomics for profiling oncogene-specific metabolic signatures of prostate cancer |
title_sort | untargeted metabolomics for profiling oncogene-specific metabolic signatures of prostate cancer |
topic | Author's View |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905328/ https://www.ncbi.nlm.nih.gov/pubmed/27308491 http://dx.doi.org/10.1080/23723556.2014.1001197 |
work_keys_str_mv | AT priolocarmen untargetedmetabolomicsforprofilingoncogenespecificmetabolicsignaturesofprostatecancer AT lodamassimo untargetedmetabolomicsforprofilingoncogenespecificmetabolicsignaturesofprostatecancer |